- ABX-1431
-
- $64.00
-
2026-07-17
- CAS:1446817-84-0
- Purity: 99.96%
- Supply Ability: 10g
|
| | ABX-1431 Basic information |
| Product Name: | ABX-1431 | | Synonyms: | CS-2856;ABX1431;ABX 1431;ABX-1431;1-Piperazinecarboxylic acid, 4-[[2-(1-pyrrolidinyl)-4-(trifluoromethyl)phenyl]methyl]-, 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ester;1,1,1,3,3,3-hexafluoropropan-2-yl
4-{[2-(pyrrolidin-1-yl)-4-(trifluoromethyl)phenyl]me
thyl}piperazine-1-carboxylate;1,1,1,3,3,3-Hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate;ABX-1431,inhibit,ABX 1431,Monoacylglycerol lipase,ABX1431,MAGL,Inhibitor;1,1,1,3,3,3-Hexafluoro-2-propyl 4-[2-(1-Pyrrolidinyl)-4-(trifluoromethyl)benzyl]piperazine-1-carboxylate | | CAS: | 1446817-84-0 | | MF: | C20H22F9N3O2 | | MW: | 507.39 | | EINECS: | | | Product Categories: | | | Mol File: | 1446817-84-0.mol |  |
| | ABX-1431 Chemical Properties |
| storage temp. | -20°C | | solubility | Soluble in DMSO (>25 mg/ml) | | form | solid | | color | White | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. | | InChI | InChI=1S/C20H22F9N3O2/c21-18(22,23)14-4-3-13(15(11-14)31-5-1-2-6-31)12-30-7-9-32(10-8-30)17(33)34-16(19(24,25)26)20(27,28)29/h3-4,11,16H,1-2,5-10,12H2 | | InChIKey | SQZJGTOZFRNWCX-UHFFFAOYSA-N | | SMILES | N1(C(OC(C(F)(F)F)C(F)(F)F)=O)CCN(CC2=CC=C(C(F)(F)F)C=C2N2CCCC2)CC1 |
| | ABX-1431 Usage And Synthesis |
| Description | ABX-1431 (1446817-84-0) is a potent (IC50 = 14 nM in vitro, 2.2 nM in human PC3 cells) and very selective (>100-fold over hABHD6, >200-fold over hPLA2G7) inhibitor of monoacylglycerol lipase (MAGL).1 Active in a rat formalin pain test at 3mg/kg. Orally bioavailable and CNS penetrant. | | Uses | Elcubragistat (ABX-1431) is a highly potent, selective, and orally available, CNS-penetrant monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 14 nM. | | Preparation |
Synthesis route for ABX-1431:
| | in vivo | Elcubragistat (ABX-1431) inhibits MGLL activity in rodent brain (ED50=0.5-1.4 mg/kg), increases brain 2-AG concentrations, and suppresses pain behavior in the rat formalin pain model[1]. | | References | [1] JUSTIN S. CISAR. Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders[J]. Journal of Medicinal Chemistry, 2018, 61 20: 9062-9084. DOI:10.1021/acs.jmedchem.8b00951
[2] Hentsch, Axel, et al. “Highly Specific Miniaturized Fluorescent Monoacylglycerol Lipase Probes Enable Translational Research.” Journal of the American Chemical Society, 2025, pp. 10188–202, https://doi.org/10.1021/jacs.4c15223.
[3] Aida*, Jumpei, et al. “Design, Synthesis, and Evaluation of Piperazinyl Pyrrolidin-2-Ones as a Novel Series of Reversible Monoacylglycerol Lipase Inhibitors.” Journal of Medicinal Chemistry, 61 20, 2018, pp. 9205–17, https://doi.org/10.1021/acs.jmedchem.8b00824. |
| | ABX-1431 Preparation Products And Raw materials |
|